Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [2]. Summary by Sections Allegations - The lawsuit claims that Baxter's Novum LVP product experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address them [2]. - The company's attempts to mitigate these issues through customer alerts were deemed insufficient, as design flaws persisted [2]. - There was a heightened risk that customers would be instructed to take existing Novum LVPs out of service, and Baxter would halt all new sales of these pumps [2]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [2]. Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025 [2]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially be appointed as lead plaintiffs [3]. - Registration allows shareholders to receive updates throughout the lifecycle of the case [3]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Baxter business and prospects, resulting in its stock trading at inflated prices. ...

Core Insights - Baxter International Inc. is a global healthcare technology company with a market cap of $11.8 billion, specializing in essential hospital and renal-care products [1] - The company is expected to announce its fiscal third-quarter earnings on October 30, with analysts predicting a profit of $0.60 per share, a 25% decrease from the previous year's $0.80 per share [2] - Analysts forecast an EPS of $2.45 for the current year, representing a 29.6% increase from $1.89 in fiscal 2024, and a further rise to $2.60 in FY2026 [3] Stock Performance - BAX stock has declined by 37.3% over the past year, underperforming the S&P 500 Index's 16.9% gain and the Health Care Select Sector SPDR Fund's 2.3% dip [4] - Recent pressures on BAX shares include a 3% drop on October 10 due to market-wide sell-offs linked to trade tensions with China [5] - A 3.7% decline occurred on September 25 following a U.S. Commerce Department investigation into medical equipment imports, raising concerns about potential tariffs and supply chain disruptions [6] Analyst Ratings - The consensus opinion on BAX stock is neutral, with an overall "Hold" rating from 16 analysts: three recommend "Strong Buy," twelve suggest "Hold," and one advises "Moderate Sell" [7] - The average analyst price target for BAX is $27.71, indicating a potential upside of 20.4% from current levels [7]

Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and systemic defects in its Novum IQ Large Volume Pump, which have resulted in significant patient risks and a notable decline in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled "Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc." and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter and its executives violated the Securities Exchange Act of 1934 by making false statements and failing to disclose critical information regarding the Novum LVP [3]. Group 2: Allegations Against Baxter - The lawsuit claims that the Novum LVP had systemic defects leading to malfunctions such as underinfusion and overinfusion, posing serious risks to patients [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures [3]. - On July 31, 2025, Baxter announced a voluntary pause in shipments and installations of the Novum LVP, which led to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Baxter International Inc. related to alleged violations of federal securities laws due to misleading statements about the Novum LVP device, which has been linked to serious malfunctions and patient risks [3][5]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in Baxter between February 23, 2022, and July 30, 2025, to discuss their legal rights [1][3]. - A federal securities class action has been filed against Baxter, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [3][7]. Group 2: Allegations Against Baxter - The complaint alleges that Baxter and its executives made false statements and failed to disclose systemic defects in the Novum LVP, which led to malfunctions that could cause serious injury or death [5]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of product withdrawal from the market [5]. Group 3: Stock Impact - The true extent of the alleged fraud was revealed on July 31, 2025, when Baxter announced a voluntary pause in shipments and installations of the Novum LVP, resulting in a 22.4% drop in stock price, closing at $21.76 [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International Inc. for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of Illinois, captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International Inc., et al., No. 1:25-cv-12672 [3]. - Investors have until December 15, 2025, to request to lead the case [3]. Group 2: Product Issues - Baxter's Novum IQ Large Volume pump, a key growth driver, has faced serious malfunctions, including under-infusion and over-infusion, which jeopardized patient safety [4][5]. - The company previously claimed that the Novum LVP had advanced safety features and that the rollout in Canada would help resolve any issues [5]. Group 3: Stock Impact - On July 31, 2025, Baxter announced a voluntary pause on shipments and installations of the Novum LVP, leading to a stock price drop of $6.29 per share, or over 22%, from $28.05 to $21.76 [6].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements and undisclosed systemic defects in its Novum IQ Large Volume Pump, which have resulted in serious patient risks and a significant drop in stock price [3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that Baxter's Novum IQ Large Volume Pump had systemic defects leading to malfunctions that posed risks of serious injury or death to patients [3]. Group 2: Allegations Against Baxter - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to the Novum LVP but failed to adequately address these issues [3]. - On July 31, 2025, Baxter announced a voluntary and temporary pause in shipments and installations of the Novum LVP, which contributed to a more than 22% drop in the company's stock price [4]. Group 3: Legal Process and Representation - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status [5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose critical information about the Novum LVP, including systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures, leading to continued harm [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to July 30, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for violations of federal securities laws, alleging misleading statements regarding the safety and efficacy of its Novum LVP medical devices during the specified Class Period [1][2]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter securities between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter made false statements and failed to disclose critical information about the Novum LVP, including systemic defects leading to malfunctions that posed serious risks to patients [2]. Allegations Against Baxter - Specific allegations include: - Systemic defects in the Novum LVP causing underinfusion, overinfusion, and non-delivery of fluids [2]. - Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [2]. - Inadequate remedial measures were taken by Baxter to address these defects, despite ongoing design flaws [2]. - Increased risk of customers removing Novum LVPs from service and halting new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [2]. Impact on Investors - Following the revelation of these issues, Baxter's stock price declined significantly, resulting in substantial losses for investors [3]. - Investors who suffered losses exceeding $250,000 are encouraged to participate in the lawsuit, with a deadline to act by December 15, 2025 [3]. About the Law Firm - Lowey Dannenberg P.C. specializes in representing investors who have suffered financial losses due to corporate fraud and has a history of recovering billions for clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request to be appointed as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a history of securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [5].